Mitofusin Activator MASM7 HR2 Domain Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective activators for mitofusins, which are crucial for regulating mitochondrial dynamics and treating various diseases such as neurological disorders, cardiovascular diseases, and cancers, as existing chemical probes have unclear mechanisms of action and potential off-target effects.
Innovation Solution
Development of a small molecule, MASM7, that directly binds to the HR2 domain of mitofusin 2, promoting the pro-tethering conformation and inducing mitochondrial fusion, thereby activating mitofusins to treat a range of diseases including neurological disorders, cardiovascular disorders, and cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing chemical probes are used to induce mitochondrial fusion, then fusion can be achieved, but the mechanism of action is unclear and off-target effects occur
Solution Approach 1:
The patent introduces MASM7 as a specific intermediary compound that directly binds to the HR2 domain of mitofusin 2 to induce conformational change and mitochondrial fusion. This intermediary approach provides a clear mechanism of action by mediating between the drug and the target protein, ensuring specific activation without off-target effects.
Solution Approach 2:
The patent utilizes conformational change as a key parameter to activate mitofusin. By inducing a specific conformational change in the HR2 domain through MASM7 binding, the patent achieves reliable and specific mitofusin activation, transforming the inactive state to an active state through controlled parameter modification.
2Reliability
If indirect mechanisms like USP30 inhibition are used to induce fusion, then fusion can be achieved, but other cellular processes involving USP30 are impacted
Solution Approach 1:
The patent extracts and targets only the specific HR2 domain of mitofusin 2, separating this target from other cellular components. By designing MASM7 to bind specifically to this extracted target domain, the patent achieves selective activation of mitofusin without affecting other cellular processes, eliminating off-target effects.
Solution Approach 2:
MASM7 serves as a highly specific intermediary that directly connects to the HR2 domain of mitofusin 2, providing a dedicated pathway for fusion induction that does not involve USP30 or other cellular processes. This intermediary approach ensures that only the intended target is affected.
Data Source
AI summary
Activators of mitofusins and their uses in treatment of diseases and disorders are disclosed.